Category

Commentary

AAIC White Paper July 19 2017

By | Commentary

STATE OF THE ART AT AAIC 2017 This year’s Alzheimer’s Association International Conference (AAIC) is the largest yet with 5,600 experts from around the world representing medical institutions, academia and industry. It is striking that the field now appears to have reached a consensus on the central role of toxic…

Read More

Critical Insight: Toxic soluble Amyloid beta oligomers (“prions”), not plaque, drive pathogenesis in Alzheimer’s disease

By | Commentary

Critical Insight:  Toxic soluble Amyloid beta oligomers (“prions”), not plaque, drive pathogenesis in Alzheimer’s disease Refinement of the Amyloid beta cascade hypothesis – Prions vs. Plaque The presence of Amyloid beta (Aβ) plaque is a hallmark of Alzheimer’s disease (AD) and several clinical trials have been undertaken to reduce or…

Read More

Executive Chairman’s Note: August 3, 2016 – Highlights from the AAIC (Alzheimer’s Association International Conference) meeting held in Toronto July 23-28, 2016

By | Commentary

Executive Chairman’s Note:   August 3, 2016 Highlights from the AAIC (Alzheimer’s Association International Conference) meeting held in Toronto July 23-28, 2016 The AAIC meeting was very positive for ProMIS Neurosciences. Most of our scientific and management team were able to attend. We shared updated data about our programs and proprietary…

Read More

The Root Cause of Alzheimer’s: Amyloid-beta and Tau prions

By | Commentary

The Root Cause of Alzheimer’s:  Amyloid-beta and Tau prions ProMIS Science team’s review of the Alzheimer’s Scientific Literature Introduction to this White Paper ProMIS Neurosciences is focused on the discovery and development of precision treatments for neurodegenerative diseases.  Novel therapeutic candidates designed to specifically target the neurotoxic, prion-like strains of…

Read More